Regeneron is a leading biotechnology company that discovers, develops, and commercializes life-transforming medicines for people with serious medical conditions. Known for a science-first approach, the firm utilizes proprietary technology platforms to translate genetic insights into human antibody treatments.
Regeneron's unique value proposition is its VelociSuite technology, specifically the VelocImmune platform, which enables the rapid generation of fully human monoclonal antibodies combined with a physician-scientist leadership team focused on internal innovation.
AI Visibility Score
Regeneron Pharmaceuticals, Inc. has an AI visibility score of 82/100, rated as moderate. This score reflects how often and how prominently Regeneron Pharmaceuticals, Inc. appears in responses from AI assistants like ChatGPT, Claude, and Gemini.
AI Perception Summary
Regeneron Pharmaceuticals occupies a paradoxical position in AI search, capturing high-intent procurement interest while remaining surprisingly absent from core clinical research and physician advocacy discussions. While the brand successfully anchors itself as a trusted partner for hospital pharmacy decision-makers, it currently cedes the critical narrative space where clinical researchers and specialists define standard-of-care treatments.
Strengths
- Secured a high-visibility position in AI Overviews for queries regarding reliable pharmaceutical partners.
- High resonance with hospital pharmacy procurement personas, ensuring the brand is visible where high-volume therapeutic decisions are made.
Visibility Gaps
- Total invisibility across chronic condition treatment research queries, including biologics for eczema, asthma, and rheumatoid arthritis.
- Complete lack of presence in specialized ophthalmological care discussions, despite strong competitive activity in this therapeutic area.
- Failure to penetrate the academic clinical researcher persona, a key group for establishing long-term clinical credibility.
Competitors in AI Recommendations
- F. Hoffmann-La Roche Ltd. (Genentech, Faricimab): 1 mentions
- Johnson & Johnson (Darzalex, Stelara): 1 mentions
- Merck & Co., Inc. (Keytruda): 1 mentions
- AbbVie Inc. (Humira, Skyrizi, Rinvoq): 1 mentions
- AstraZeneca PLC (Tezspire, Imfinzi): 1 mentions
- Amgen Inc. (Prolia, Vectibix): 1 mentions
- Bristol-Myers Squibb (Opdivo, Yervoy): 1 mentions
- Genmab A/S (Darzalex): 1 mentions
Categories: Healthcare